Roger BaylisDuffield - Plandai Biotech Chairman of the Board, CEO, CFO
| PLPL Stock | USD 0.0002 0.0001 100.00% |
Chairman
Mr. Roger BaylisDuffield is Chairman of the Board, Chief Executive Officer, Chief Financial Officer of the Company. which he cofounded 2001 as a private Irish research company, Global Energy Solutions Corporation Limited, which merged into Planda in 2011 since 2017.
| Age | 80 |
| Tenure | 7 years |
| Phone | 44 91 7900 9829 |
| Web | https://www.plandaibiotech.com |
Plandai Biotech Management Efficiency
The company has return on total asset (ROA) of (0.2096) % which means that it has lost $0.2096 on every $100 spent on assets. This is way below average. Plandai Biotech's management efficiency ratios could be used to measure how well Plandai Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| MD MPH | Mineralys Therapeutics, Common | 47 | |
| Eric Weisblum | Silo Pharma | 54 | |
| Mark Emalfarb | Dyadic International | 68 | |
Management Performance
| Return On Asset | -0.21 |
Plandai Biotech Management Team
Elected by the shareholders, the Plandai Biotech's board of directors comprises two types of representatives: Plandai Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Plandai. The board's role is to monitor Plandai Biotech's management team and ensure that shareholders' interests are well served. Plandai Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Plandai Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Callum BaylisDuffield, Chief Pres | ||
| Roger BaylisDuffield, Chairman of the Board, CEO, CFO | ||
| Ezra Jones, Vice President of Sales and Marketing |
Plandai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Plandai Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.21 | |||
| Operating Margin | (12.22) % | |||
| Current Valuation | 236.87 K | |||
| Shares Outstanding | 263.19 M | |||
| Price To Earning | (0.32) X | |||
| Price To Sales | 1.04 X | |||
| Revenue | 411.99 K | |||
| Gross Profit | (768.91 K) | |||
| EBITDA | (2.1 M) | |||
| Net Income | (4.01 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.